Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study

Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to compare the efficacy of rituximab (RTX) followed by belimumab or telitacicept in a real-world cohort.Metho...

Full description

Saved in:
Bibliographic Details
Main Authors: Fei Han, Hong Pan, Yi Yang, Jianghua Chen, Jing Xue, Lan Lan, Yiting Chen, Pingping Ren, Yaomin Wang, Xin Lei, Jianhang Xu, Xiaochan Chen, Qiankun Zhang, Junni Wang, Nan Shi, Liangliang Chen, Lie Jin
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/12/1/e001296.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://lupus.bmj.com/content/12/1/e001296.full

Similar Items